Professor Christopher Buckley, University of Birmingham and University of Oxford, UK
Professor Harris Perlman, Northwestern University, USA
Click here to view which articles have been shared the most in the last month.
Meet this month's featured authors!
Aims and scope
A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care.
Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease, and affects an estimated 0.24% of the global population. As RA is a chronic disease requiring long-term treatment, it is important to assess the long-term effectiveness and safety of RA therapies. Long-term extension (LTE) studies offer the ability to observe and evaluate long-latency safety effects, such as malignancies and cardiovascular events, as well as short-latency events, such as infections.
In this article, Wollenhaupt et al present the final data for the ORAL Sequel LTE study evaluating the safety and efficacy of tofacitinib in patients with RA.
Annual Journal Metrics
56 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
121 days from submission to acceptance
33 days from acceptance to publication
1,140 Altmetric Mentions